The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia
| Autor: | Ryan J. Daley, Amanda N. Seddon, Amber C. King, Troy Z. Horvat, Adebayo Ogunniyi, Larry W Buie |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Lymphoblastic Leukemia medicine.medical_treatment T-Lymphocytes Food and drug administration 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Antibodies Bispecific Medicine Humans Pharmacology (medical) B-Lymphocytes Receptors Chimeric Antigen Adult patients business.industry Antibodies Monoclonal B-cell acute lymphoblastic leukemia Immunotherapy Precursor Cell Lymphoblastic Leukemia-Lymphoma 030220 oncology & carcinogenesis Immunology Blinatumomab Car t cells business 030215 immunology medicine.drug |
| Zdroj: | The Annals of pharmacotherapy. 52(3) |
| ISSN: | 1542-6270 |
| Popis: | Objective: To review the pharmacology, efficacy, and safety of Food and Drug Administration approved and promising immunotherapy agents used in the treatment of acute lymphoblastic leukemia (ALL). Data Sources: A literature search was performed of PubMed and MEDLINE databases (1950 to July 2017) and of abstracts from the American Society of Hematology and the American Society of Clinical Oncology. Searches were performed utilizing the following key terms: rituximab, blinatumomab, inotuzumab, ofatumumab, obinutuzumab, Blincyto, Rituxan, Gazyva, Arzerra, CAR T-cell, and chimeric antigen receptor (CAR). Study Selection/Data Extraction: Studies of pharmacology, clinical efficacy, and safety of rituximab, ofatumumab, obinutuzumab, inotuzumab, blinatumomab, and CAR T-cells in the treatment of adult patients with ALL were identified. Data Synthesis: Conventional chemotherapy has been the mainstay in the treatment of ALL, producing cure rates of approximately 90% in pediatrics, but it remains suboptimal in adult patients. As such, more effective consolidative modalities and novel therapies for relapsed/refractory disease are needed for adult patients with ALL. In recent years, anti-CD20 antibodies, blinatumomab, inotuzumab, and CD19-targeted CAR T-cells have drastically changed the treatment landscape of B-cell ALL. Conclusion: Outcomes of patients with relapsed disease are improving thanks to new therapies such as blinatumomab, inotuzumab, and CAR T-cells. Although the efficacy of these therapies is impressive, they are not without toxicity, both physical and financial. The optimal sequencing of these therapies still remains a question. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|